Free Trial

New York State Teachers Retirement System Has $5.76 Million Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers Health logo with Medical background

New York State Teachers Retirement System lifted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 95.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 194,795 shares of the company's stock after purchasing an additional 94,983 shares during the period. New York State Teachers Retirement System owned 0.09% of Hims & Hers Health worth $5,756,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HIMS. Amalgamated Bank lifted its holdings in shares of Hims & Hers Health by 50.7% in the first quarter. Amalgamated Bank now owns 84,197 shares of the company's stock worth $2,488,000 after buying an additional 28,310 shares in the last quarter. Sunbelt Securities Inc. boosted its stake in shares of Hims & Hers Health by 183.3% in the 1st quarter. Sunbelt Securities Inc. now owns 1,700 shares of the company's stock valued at $50,000 after purchasing an additional 1,100 shares in the last quarter. Tsfg LLC bought a new position in shares of Hims & Hers Health during the first quarter valued at about $46,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Hims & Hers Health by 48.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 17,248 shares of the company's stock worth $536,000 after purchasing an additional 5,655 shares during the last quarter. Finally, Kessler Investment Group LLC purchased a new stake in shares of Hims & Hers Health in the 1st quarter worth about $3,508,000. 63.52% of the stock is currently owned by institutional investors.

Insider Activity at Hims & Hers Health

In related news, insider Michael Chi sold 17,102 shares of the company's stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total value of $1,021,844.50. Following the sale, the insider owned 278,654 shares of the company's stock, valued at approximately $16,649,576.50. This represents a 5.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Oluyemi Okupe sold 23,107 shares of the stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the transaction, the chief financial officer directly owned 63,222 shares in the company, valued at approximately $2,987,239.50. This represents a 26.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold 692,006 shares of company stock valued at $34,857,872 in the last 90 days. 13.71% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Truist Financial set a $45.00 price target on shares of Hims & Hers Health in a research report on Tuesday, June 24th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price target for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Finally, Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus target price of $39.58.

View Our Latest Analysis on Hims & Hers Health

Hims & Hers Health Trading Up 0.8%

HIMS traded up $0.36 during trading hours on Monday, hitting $48.34. 27,287,587 shares of the company's stock were exchanged, compared to its average volume of 23,484,617. The firm has a market cap of $10.82 billion, a P/E ratio of 70.06, a price-to-earnings-growth ratio of 1.76 and a beta of 2.02. The firm has a 50 day moving average of $52.23 and a 200 day moving average of $40.38. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The business had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The company's revenue for the quarter was up 110.7% compared to the same quarter last year. During the same period last year, the firm posted $0.05 earnings per share. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Profile

(Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Recommended Stories

Institutional Ownership by Quarter for Hims & Hers Health (NYSE:HIMS)

Should You Invest $1,000 in Hims & Hers Health Right Now?

Before you consider Hims & Hers Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.

While Hims & Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines